Sector News

Lundbeck names new CEO after first-quarter loss

May 6, 2015
Life sciences
Danish pharmaceutical company H.Lundbeck A/S said Wednesday it had appointed a new chief executive after the company swung into a net loss amid heightened uncertainty during the first quarter.
 
Lundbeck, which has been facing tough competition and a price erosion of some of its mature products, said it had named Kare Schultz as its new president and chief executive officer starting May 20.
 
Prior to joining Lundbeck, Mr. Schultz forged a long career at Lundbeck’s bigger Danish rival, the insulin maker Novo Nordisk A/S NVO, -2.32% where he rose to become the company’s chief operating officer.
 
However, Mr. Schultz resigned from Novo last month when the company’s board decided that Novo’s current CEO Lars Rebien Sorensen should remain in his position for the time being.
 
Lundbeck’s quarterly net loss for the three months through March was 81 million Danish kroner ($12.2 million), compared with a net profit of DKK331 million in the year-earlier period.
 
The net loss figure was precisely the same as the median analyst forecast in a poll carried out by financial data provider SME Direkt.
 
Lundbeck’s quarterly revenue was DKK3.56 billion, slightly down from DKK3.59 billion a year earlier and above a median forecast of DKK3.20 billion.
 
The company said that it is experiencing unusually high uncertainty as it invests in the launch and late-stage development of new products.
 
Lundbeck kept its full-year 2015 guidance unchanged. It is expecting its core revenue to be between DKK13.2 billion and DKK13.7 billion in 2015, compared with DKK13.5 billion in 2014, and its core operating profit to be at zero, down from DKK1.2 billion in 2014.
 
“The outlook reflects constant exchange rates and expectations for continued robust performance of the portfolio of strategic core products which partly offsets the continued generic erosion of mature products,” the company said.
 
By Juhana Rossi 
 
Source: Wall Street Journal via MarketWatch

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

How can we help you?

We're easy to reach